MedTrace Logo

Lipopolysaccharide Adsorption At Septic Shock

NCT04827407 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2024-09-19

No results posted yet for this study

Summary

Sepsis is a global healthcare burden sepsis, it reaches 20-30 million cases annually (WHO data). Numerous studies have shown that extracorporeal hemoperfusion therapies that eliminate endotoxin and\\or excess of cytokines improve treatment outcomes in patients with septic shock. The main purpose of the study is to obtain new data on the efficacy and safety of the Efferon LPS device in extracorporeal therapy in patients with abdominal sepsis complicated by septic shock.

Conditions

  • Septic Shock

Interventions

DEVICE

Efferon LPS hemoperfusion

Hemoperfusion using continuous extracorporeal LPS adsorption with Efferon LPS therapeutic device during a period of 24h immediately following admission to the intensive care unit

Sponsors & Collaborators

  • Ligand Research, LLC

    collaborator NETWORK

  • Efferon JSC

    lead INDUSTRY

Principal Investigators

  • Sergey Rey, MD, PhD · N. V. Sklifosovsky Moscow Research Institute of Emergency, Moscow, Russia

  • Vladimir Kulabukhov, MD, PhD · N. V. Sklifosovsky Moscow Research Institute of Emergency, Moscow, Russia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-23
Primary Completion
2022-03-30
Completion
2022-08-30

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04827407 on ClinicalTrials.gov